Ultimark Products sells Porcelana Day Skin Lightening Cream, an unapproved and misbranded hydroquinone skin-bleaching drug, FDA says.
What happened
FDA reviewed the product label and labeling on Porcelana.com, where the cream is sold, and found claims that it fades dark spots and lightens skin, with hydroquinone 2% as the active ingredient. FDA determined the product is a skin-bleaching drug subject to section 505G; because FDA had proposed that OTC skin-bleaching products including hydroquinone are not generally recognized as safe and effective, the product is deemed a new drug needing an approved application. No approved application is in effect, and FDA also cites it as misbranded.
What FDA found
The company sells a skin-lightening cream containing 2% hydroquinone as an unapproved new drug without an FDA-approved drug application.
FD&C Act section 505(a), 21 U.S.C. 355(a)The product is misbranded because it is a nonprescription drug subject to section 505G but lacks an approved application and does not comply with section 505G.
FD&C Act section 502(ee), 21 U.S.C. 352(ee); section 505G, 21 U.S.C. 355hThe skin-bleaching drug is deemed a new drug because FDA proposed that OTC skin-bleaching products with hydroquinone are not generally recognized as safe and effective.
FD&C Act section 201(p)(1); section 505G(a)(4), 21 U.S.C. 355h(a)(4)
What FDA wants
Respond in writing within 15 working days describing what you have done to correct the violations and prevent recurrence, or explain why you believe the product is not in violation. If you cannot fully address the violations in that time, state the reasons for delay and a completion schedule.
Who should pay attention
- retailers and online marketplaces selling Porcelana or hydroquinone skin-lightening creams
- brands and contract manufacturers making OTC skin-bleaching products
- regulatory teams handling drug listing and OTC drug compliance
This is a summary. Read the original letter on fda.gov.